Impact and risk factors of non-adherence to 5-aminosalicylates in quiescent ulcerative colitis evaluated by an electronic management system
- 24 Downloads
Background and objective
To determine the impact of non-adherence to 5-Aminosalicylates (5-ASA) on the risk of flares and to identify risk factors of non-adherence.
Observational, cohort study of ulcerative colitis (UC) patients in clinical remission at least 6 months on 5-ASA monotherapy maintenance prescribed by an electronic management program. Adherence was considered when 80% of the prescribed 5-ASA had been dispensed at the pharmacy. The study analyzed the existence and degree of 5-ASA adherence, disease course, UC phenotypic expression, and 5-ASA dose and regimen, and consumption of non-UC chronic drugs during 2-year follow-up.
The study included 274 patients, 49% males with a median age of 38 (27–49) years old. Overall, 41% of patients were non-adherent to 5-ASA. Risk of flares was reduced in the adherent group (36% vs 54%; OR = 0,484; p = 0,004), mainly the mild ones (26% vs 38%; OR = 0,559; p = 0,031). Non-adherence was associated with younger age at diagnosis (32 (26–45) vs 41.5 (21–50), p = 0.000) and no-consumption of other chronic treatments (1.1 vs 2.1; OR = 1709; p = 0,048).
Non-adherence to 5-ASA evaluated by the pharmaceutical management system was at 41% with a higher risk of relapse. Younger patients and patients who do not receive non-UC chronic treatments showed lower adherence rate.
KeywordsColitis, ulcerative Aminosalicylic acids Treatment adherence and compliance Treatment outcome Symptom flare-up
Conception and design of the study: Ballester MP, Martí-Aguado D, Fullana M, Bosca-Watts MM, and Minguez M
Acquisition of data: Ballester MP, Martí-Aguado D, Fullana M, Romero E, Sanchez A, Navarro P, and Anton R
Analysis and interpretation of data: Ballester MP, Martí-Aguado D, Bosca-Watts MM, Tosca J, and Minguez M
Manuscript writing: Ballester MP, Martí-Aguado D, Bosca-Watts MM, Tosca J, Mora F, and Minguez M
All listed authors approved the final version.
Compliance with ethical standards
Conflict of interest
M. Minguez has served as a speaker, a consultant, and advisory member for or has received research funding from MSD, Abbvie, Pfizer, Janssen, Shire Pharmaceuticals, Allergan.
M.M. Bosca-Watts declares educational activities, research projects, scientific meetings, and advisory boards sponsored by MSD, Ferring, Abbvie, Janssen, and Takeda.
Informed consent statement
All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Institutional review board approval
The study was reviewed and approved by the University Clinic Hospital of Valencia, Institutional Review Board.
- 1.Hardbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, Kucharzik T, Molnár T, Raine T, Sebastian S, de Sousa HT, Dignass A, Carbonnel F, European Crohn’s and Colitis Organisation (ECCO) (2017) Third European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohn Colitis 11:769–784. https://doi.org/10.1093/ecco-jcc/jjx009 CrossRefGoogle Scholar
- 2.Travis SP, Higgins PD, Orchard T, Van Der Woude CJ, Panaccione R, Bitton A, O’Morain C, Panés J, Sturm A, Reinisch W, Kamm MA, D’Haens G (2011) Review article: defining remission in ulcerative colitis. Aliment Pharmacol Ther 34:113–124. https://doi.org/10.1111/j.1365-2036.2011.04701.x CrossRefGoogle Scholar
- 10.Kawakami A, Tanaka M, Nishigaki M, Naganuma M, Iwao Y, Hibi T, Sanada H, Yamamoto-Mitani N, Kazuma K (2013) Relationship between non-adherence to aminosalicylate medication and the risk of clinical relapse among Japanese patients with ulcerative colitis in clinical remission: a prospective cohort study. J Gastroenterol 48:1006–1015. https://doi.org/10.1007/s00535-012-0721-x CrossRefGoogle Scholar
- 11.Higgins P, Rubin DT, Kaulback K, Schoendfield PS, Kane SV (2008) Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and costs of ulcerative colitis flares. Aliment Pharmacol Ther 29:247–257. https://doi.org/10.1111/j.1365-2036.2008.03865.x. CrossRefGoogle Scholar
- 12.Khan N, Abbas AM, Bazzano LA, Koleva YN, Krousel-Wood M (2012) Long-term oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10-years retrospective cohort from the veterans affairs healthcare system. Aliment Pharmacol Ther 36:755–764. https://doi.org/10.1111/apt.12013 CrossRefGoogle Scholar
- 17.Bermejo F, López-San Román A, Algaba A, Guerra I, Valer P, García-Garzón S, Piqueras B, Villa C, Bermejo A, Rodríguez-Agulló JL (2010) Factors that modify therapy adherence in patients with inflammatory bowel disease. J Crohn Colitis 4:422–426. https://doi.org/10.1016/j.crohns.2010.01.005 CrossRefGoogle Scholar
- 18.Algaba A, Guerra I, Garcia Garcia de Pareces A, Hernández Tejero M, Ferre C, Bonillo D, Aguilera L, López-Sanromán A, Bermejo F (2017) What is the real life manteinance mesalazine dose in ulcerative colitis? Rev Esp Enferm Dig 109(2):114–121. https://doi.org/10.17235/reed.2016.4620/2016. Google Scholar
- 21.Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K, Jewell DP, Karban A, Loftus EV Jr, Peña AS, Riddell RH, Sachar DB, Schreiber S, Steinhart AH, Targan SR, Vermeire S, Warren BF (2005) Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 19(Suppl):5A–36ACrossRefGoogle Scholar
- 23.Singh S, Proudfoot JA, Dulai PS, Jairath V, Fumery M, Xu R, Feagan BG, Sandborn WJ (2018) No benefit of concomitant 5-aminosalicylates in patients with ulcerative colitis escalated to biologic therapy: pooled analysis of individual participant data from clinical trials. Am J Gastroenterol. https://doi.org/10.1038/s41395-018-0144-2
- 25.Keil R, Keil R, Wasserbauer M, Zádorová Z, Kojecký V, Hlava Š, Št'ovíček J, Chudý J, Roznětinská M, Drábek J, Kubišová N, Lochmannová J (2018) Adherence, risk factors of non-adherence and patient's preferred treatment strategy of mesalazine in ulcerative colitis: multicentric observational study. Scand J Gastroenterol 53(4):459–465. https://doi.org/10.1080/00365521.2018.1451915 CrossRefGoogle Scholar